ARTICLE | Clinical News
Brilinta ticagrelor: Phase III data
May 18, 2009 7:00 AM UTC
Top-line data from the double-blind, double-dummy, international Phase III PLATO trial in 18,624 patients showed that Brilinta met the primary endpoint of significantly increasing the time to a recurr...